focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
The comments on here tend to give a false impression of how significant the news is
Looks more like a deep dive into old data to me.
Or he's just talking about SNG001, the clinical trials didn't have the outcome we wanted, and it won't be available to patients in 2022.
At first sight this comment is the most positive thing to come out of SNG for a while. I have some questions that better informed posters can no doubt help me with...
A new treatment? Does that mean not SNG001?
What trials are they on that are current?
When he says "available" does he mean in trials? Surely not as a commercial drug?
Mildly encouraging
Yes but what Kevin says is correct.
"No treatments are being investigated"
Dunk. Why?
"Wouldnt be surprised if Poly ( together with another party) is thebuyer
Their best chance to make a good return"
How would that work?
I think Mr Costs might have been taking the mickey.
"under embargo due to containing commercially sensitive information"
I hope so, but I doubt it
Prove me wrong RM
RM one of 164 speakers.
Probably nothing new to say.
I think this will be a bit of a non-event. I do not expect it to impact the share price either way. We need platform trial for that.
Charts schmarts
Rambler still off most investors’ radar
It has messed up too often for people who don’t know it to believe unquantified promises.
It will to get some attention when it publishes financials showing a profit.
@1111112
There's no robust evidence of Hydroxychloroquine curing Covid19.
Well said Doc.Daneeka
I'm very much looking forward to seeing the numbers, as well as some encouraging P/L figures
Can’t see Tommy D’s post. Has it been deleted?
"Just thought I'd quickly check in on here. Wasn't all this "peer reviewed" crap done to death a couple of weeks back?"
Yes it was. Mani set it off again by reposting the link to the Medicom report on the ATS conference.
What was established at the time was the report was "peer reviewed" to make sure it reflected what was said at the conference, but that there was no suggestion of any peer review of the SPRINTER trial, data, results or deep dive.
@Manifesto said "Now Doc.Daneeka You are making things up again..ATS have published a great review on SPRINTER...
Does that not fit with your narrative?? Let's just stick to what is real shall we......."
ATS have not, as far as I am aware, published a great review on SPRINTER. The review that Manifesto links to is not such a thing. It's a review of the conference, written and published by Medicom, a commercial organisation financed by advertising/sponsorship. It's purpose seems to be to keep interested parties in touch with what is being reported at conferences without having to actually attend.